The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.

Eva Segelov; Subotheni Thavaneswaran; Paul  Waring; Jayesh Desai; Kirsty Mann; Maria Elena Elez; Lorraine A Chantrill; Nick Pavlakis; Louise Nott; C Underhill; Mustafa Khasraw; Harpreet Wasan; Fortunato Ciardiello; Michael J Jefford; Warren Joubert; Andrew Mark Meurisse Haydon; Christos Karapetis; Tim J. Price; Kate Wilson; Jeremy Shapiro

doi:10.1016/S0959-8049(15)30078-2

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.

Eva Segelov, Subotheni Thavaneswaran, Paul Waring, Jayesh Desai, Kirsty Mann, Maria Elena Elez, Lorraine A Chantrill, Nick Pavlakis, Louise Nott, C Underhill, Mustafa Khasraw, Harpreet Wasan, Fortunato Ciardiello, Michael J Jefford, Warren Joubert, Andrew Mark Meurisse Haydon, Christos Karapetis, Tim J. Price, Kate Wilson, Jeremy Shapiro

Research output: Contribution to conference › Abstract

Original language	English
Pages	S726
Number of pages	1
DOIs	https://doi.org/10.1016/S0959-8049(15)30078-2
Publication status	Published - 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(15)30078-2

1 Poster

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation
Segelov, E., Wilson, K., Gebski, V., Waring, P., Desai, J., Nott, L., Karapetis, C., Wasan, H. & Shapiro, J., 2013, p. 155. 1 p.
Research output: Contribution to conference › Poster

Cite this

Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, M. E., Chantrill, L. A., Pavlakis, N., Nott, L., Underhill, C., Khasraw, M., Wasan, H., Ciardiello, F., Jefford, M. J., Joubert, W., Haydon, A. M. M., Karapetis, C., Price, T. J., Wilson, K., & Shapiro, J. (2015). The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.. S726. https://doi.org/10.1016/S0959-8049(15)30078-2

@conference{a3914c76f3ce4d1295585fb70f848a83,

title = "The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.",

author = "Eva Segelov and Subotheni Thavaneswaran and Paul Waring and Jayesh Desai and Kirsty Mann and Elez, {Maria Elena} and Chantrill, {Lorraine A} and Nick Pavlakis and Louise Nott and C Underhill and Mustafa Khasraw and Harpreet Wasan and Fortunato Ciardiello and Jefford, {Michael J} and Warren Joubert and Haydon, {Andrew Mark Meurisse} and Christos Karapetis and Price, {Tim J.} and Kate Wilson and Jeremy Shapiro",

year = "2015",

doi = "10.1016/S0959-8049(15)30078-2",

language = "English",

pages = "S726",

}

Segelov, E, Thavaneswaran, S, Waring, P, Desai, J, Mann, K, Elez, ME, Chantrill, LA, Pavlakis, N, Nott, L, Underhill, C, Khasraw, M, Wasan, H, Ciardiello, F, Jefford, MJ, Joubert, W, Haydon, AMM, Karapetis, C, Price, TJ, Wilson, K & Shapiro, J 2015, 'The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.', pp. S726. https://doi.org/10.1016/S0959-8049(15)30078-2

The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. / Segelov, Eva; Thavaneswaran, Subotheni; Waring, Paul et al.
2015. S726.

Research output: Contribution to conference › Abstract

TY - CONF

T1 - The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation.

AU - Segelov, Eva

AU - Thavaneswaran, Subotheni

AU - Waring, Paul

AU - Desai, Jayesh

AU - Mann, Kirsty

AU - Elez, Maria Elena

AU - Chantrill, Lorraine A

AU - Pavlakis, Nick

AU - Nott, Louise

AU - Underhill, C

AU - Khasraw, Mustafa

AU - Wasan, Harpreet

AU - Ciardiello, Fortunato

AU - Jefford, Michael J

AU - Joubert, Warren

AU - Haydon, Andrew Mark Meurisse

AU - Karapetis, Christos

AU - Price, Tim J.

AU - Wilson, Kate

AU - Shapiro, Jeremy

PY - 2015

Y1 - 2015

U2 - 10.1016/S0959-8049(15)30078-2

DO - 10.1016/S0959-8049(15)30078-2

M3 - Abstract

SP - S726

ER -